Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 60 years of age (first age group) OR over 60 years of age (second age group)~2. mentally competent to understand the nature, the scope and the consequences of the study~3. able and willing to give written informed consent prior to study entry~4. available for all the visits scheduled in the study~5. residence in the study area~6. in good health as determined by:~   1. medical history,~  2. physical examination,~  3. clinical judgment of the investigator.~Exclusion Criteria:~1. unable or unwilling to give written informed consent to participate in the study~2. suffering from an acute infectious disease~3. any serious disease such as:~   1. cancer (except for benign or localized skin cancer and non metastatic prostate cancer not currently treated with chemotherapy),_~  2. autoimmune disease (including rheumatoid arthritis),~  3. advanced arteriosclerotic disease or complicated diabetes mellitus,~  4. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy,~  5. acute or progressive hepatic disease,~  6. acute or progressive renal disease,~  7. congestive heart failure~4. surgery planned during the study period~5. bleeding diathesis~6. history of hypersensitivity to any component of the study medication or chemically related substances, such as allergy to eggs or egg products~7. known or suspected impairment/alteration of immune function resulting from:~   1. receipt of immunosuppressive therapy (any cortical steroid or cancer chemotherapy),~  2. receipt of immunostimulants,~  3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study,~  4. high risk for developing an immunocompromising disease within the past 6 months~8. history of drug or alcohol abuse~9. laboratory confirmed influenza disease in the past 6 months~10. received influenza vaccine within the past 6 months~11. received another vaccine or any investigational agent within the past 60 days, or planned vaccination within 3 weeks following the study vaccination~12. any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever ≥ 38°C within the past 3 days~13. pregnant women or women who refused to use a reliable contraceptive method throughout the study (180 days)~14. any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cell culture-derived influenza vaccine (cTIV) (Type: EXPERIMENTAL): None
- Egg-derived influenza virus vaccine (TIV) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete